Suggestions
Flavia Nery
Clinical Development, Neurodegenerative Disorders
Flavia Nery is a Medical Director at Biogen, where she focuses on clinical development, particularly in the field of neuroscience. Her recent work includes presenting data on BIIB113, an O-GlcNAcase inhibitor aimed at treating tauopathies, during the AD/PD conference in March 2024. This compound has shown promising results in early trials, demonstrating significant engagement with its target in the brain and a favorable safety profile.1
In addition to her role at Biogen, Nery has an academic background as an Assistant in Neuroscience at Massachusetts General Hospital and serves as an Instructor of Neurology at Harvard University. Her research primarily revolves around genetic factors related to neurodegenerative diseases.23 Before her current position, she held various roles at Biogen Idec and Massachusetts General Hospital, contributing to her extensive experience in clinical science and project management.34
Nery's educational qualifications include a postdoctoral degree from Harvard Medical School, which underlines her expertise in the field.5
